Table 3 Clinical summary of patients with Tolosa-Hunt Syndrome
From: The clinical features and outcomes of Tolosa-Hunt syndrome
Case | Sex | Age | Clinical findings | Involved CN | MRI findings | ESR (0–20) | CRP (0–5) | Treatment (per day) | Relapse | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | M | 73 | Diplopia | 6 CN | Enhanced left cavernous sinus and clinoid process | 15 | 0.9 | Oral MPD 50 mg | - | |||
2 | M | 74 | Diplopia, Ptosis | Optic nerve, 3/4/6 CN | Enlarged and enhanced left cavernous sinus/apex/optic nerve | 52 | 2.6 | Oral MPD 50 mg | 5 weeks interval | |||
3 | M | 52 | Diplopia | Optic nerve, 4 CN | Mild thickening and enhanced right cavernous sinus/apex (superior/inferior orbital fissure) | 10 | 2.5 | IV MPD 1 g | - | |||
4 | F | 46 | Diplopia, Ptosis | 3/4/6 CN | Enhanced focal triangular shaped right cavernous sinus with enlarged right superior ophthalmic vein | 21 | 0.3 | IV MPD 1 g | - | |||
5 | M | 68 | Diplopia, Ptosis | 3 CN | Enhanced focal right superior orbital fissure | 12 | 2.0 | Oral MPD 50 mg | 5 years ago | |||
6 | M | 46 | Diplopia | 6 CN | Slightly bulging of right cavernous sinus | 2 | 0.5 | Oral MPD 50 mg | - | |||
7 | M | 46 | Diplopia | 6 CN, facial nerve | Suspicious enhanced left superior orbital fissure | 10 | 0.7 | Oral MPD 50 mg | - | |||
8 | M | 69 | Diplopia | 4 CN | Enhanced left cavernous sinus/superior orbital fissure | 8 | 0.8 | Oral MPD 50 mg | - | |||
9 | M | 78 | Diplopia, Ptosis | 3/6 CN | Enlarged and enhanced left cavernous sinus | 11 | 0.7 | IV MPD 1 g | - | |||
10 | F | 42 | Diplopia, Ptosis | 3/4/6 CN | Enhanced right cavernous sinus and extending to orbital apex | 30 | 0.5 | IV MPD 1 g | - | |||
11 | M | 35 | Diplopia | Trigeminal nerve, 6 CN | Enhanced left cavernous sinus and extracranial portion of mandibular division of trigeminal nerve | 13 | 1.1 | IV MPD 1 g | - | |||